July 2017
TABLE OF CONTENTSCluster's lifeOur member's newsSave the dateCalls for projectsAround our themes

Our collaborations with the health ecosystem are essential to contribute to the activities and life of Lyonbiopole. This month, three of them highlighted our cluster's offer : scientific animation (Open Medtronic Innovation Day), economic development (employers' group) and European activities (ASSET Project ).


We wish you a wonderful summer and we hope to meet you soon at our key events.

Cluster's life

 Group of employersLyonbiopole and Axelera signed a partnership agreement with the GENIPLURI group of employers. This partnership aims to build inter-sectoral collaboration and to respond to the members' needs related to their economic development.
 Lyonbiopole partner of the European project ASSET publishes a newsletter Since 2014, Lyonbiopôle is a partner of the ASSET project which aims to define a participatory and innovative strategy for the management of epidemic and pandemic crisis. In this respect, the results of the European Citizens' Consultation were presented in April at the European Parliament and the local initiatives have been launched in 12 countries. The French partners of the project plan to consult the students in medicine on the vaccination issues in Lyon and Grenoble. [...]
 Open Innovation Day Medtronic – LyonbiopoleMedtronic Sofradim Productions and Lyonbiopole co-organized a meeting to bring together the company and the regional public/private ecosystem. 20 representatives from academic organizations and companies (from SME to large company) were invited to present their activities during the pitch session in front of Medtronic and the 50 participants. After the lunch break, Medtronic organized a tour of their facilities (collagen, textile and R&D) and B2B meetings in order to discuss enhanced collaborations.

Our member's news

 New memberSiamed’Xpress is a R&D company pionneering protein glycoengineering to develop long-lasting and better tolerated biologics, thus delivering highly active products at low dose. The company now opens an innovative technological platform to produce therapeutic antibodies of reduced immunogenicity: it aims at preventing production of anti-drug antibodies which is a major cause of resistance in current biotherapies.
 Focus onANAQUANT announces a fundraising campaign with Health Angels Rhône-Alpes. These funds will enable ANAQUANT to implement a commercial strategy in order to launch its innovation, READYBEADS, which facilitates and secures bioanalyses pharmaceutical industry .
 July 12th, 2017Erytech announces collaboration with Queen's University July 12th, 2017Poxel Appoints Kumi Sato to its Board of Directors July 19th, 2017ElsaLys Biotech and DKFZ initiate the development of ELB021
 July 20th, 2017MaaT Pharma completes patient recruitment of its Odyssée clinical trial July 24th, 2017Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15 July 28th, 2017Valneva and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus
 July 28th, 2017KOELIS awarded World Innovation Contest prize

Save the date

 PARTNERING DAYS
October 10th, 2017
Hospital-acquired infection 2017
November 14th, 2017
Private Inv¤stments Day
Décember 1st, 2017
  • NLSDays
    September 11th, 2017
  • Medica Copamed 2017
    November 13th, 2017

  • See All events

    Calls for projects

     

    EUROPE & INTERNATIONAL

  • Eurostars programme
    Before September 14th, 2017
  • COFUND 2017
    Before September 28th, 2017
  • UNITAID
    Before September 30th, 2017
  • Innovative Medicines Initiative – IMI 2
    Before October 24th, 2017
  • H2020 SME instrument
    Before November 8th, 2017
  • Around our themes

     
  • 18th Congress of the European Society for Organ Transplantation
    September 24th, 2017
  • Falling Walls Conference
    November 8th, 2017
  • Bâtiment Domilyon

    321, avenue Jean Jaurès

    69007 Lyon

    Tel. : +33 (0)4 72 76 53 30

    Fax : +33 (0)9 55 91 30 26

    www.lyonbiopole.com

    info@lyonbiopole.com

    TwitterLinkedInrss

     

    This email has been sent automatically to [[EMAIL_TO]]. Click here to unsubscribe.